BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2010 related articles for article (PubMed ID: 23700391)

  • 1. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value.
    Marisa L; de Reyniès A; Duval A; Selves J; Gaub MP; Vescovo L; Etienne-Grimaldi MC; Schiappa R; Guenot D; Ayadi M; Kirzin S; Chazal M; Fléjou JF; Benchimol D; Berger A; Lagarde A; Pencreach E; Piard F; Elias D; Parc Y; Olschwang S; Milano G; Laurent-Puig P; Boige V
    PLoS Med; 2013; 10(5):e1001453. PubMed ID: 23700391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
    Sinicrope FA; Shi Q; Smyrk TC; Thibodeau SN; Dienstmann R; Guinney J; Bot BM; Tejpar S; Delorenzi M; Goldberg RM; Mahoney M; Sargent DJ; Alberts SR
    Gastroenterology; 2015 Jan; 148(1):88-99. PubMed ID: 25305506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.
    Zhang JX; Song W; Chen ZH; Wei JH; Liao YJ; Lei J; Hu M; Chen GZ; Liao B; Lu J; Zhao HW; Chen W; He YL; Wang HY; Xie D; Luo JH
    Lancet Oncol; 2013 Dec; 14(13):1295-306. PubMed ID: 24239208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer.
    Popovici V; Budinska E; Tejpar S; Weinrich S; Estrella H; Hodgson G; Van Cutsem E; Xie T; Bosman FT; Roth AD; Delorenzi M
    J Clin Oncol; 2012 Apr; 30(12):1288-95. PubMed ID: 22393095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Validation Study for Recurrence Risk Stratification of Stage II Colon Cancer Using the 55-Gene Classifier.
    Shinto E; Oki E; Shimokawa M; Yamaguchi S; Ishiguro M; Morita M; Kusumoto T; Tomita N; Hashiguchi Y; Tanaka M; Ohnuma S; Tada S; Matsushima T; Hase K
    Oncology; 2020; 98(8):534-541. PubMed ID: 32235113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.
    Li B; Cui Y; Diehn M; Li R
    JAMA Oncol; 2017 Nov; 3(11):1529-1537. PubMed ID: 28687838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior.
    Perez-Villamil B; Romera-Lopez A; Hernandez-Prieto S; Lopez-Campos G; Calles A; Lopez-Asenjo JA; Sanz-Ortega J; Fernandez-Perez C; Sastre J; Alfonso R; Caldes T; Martin-Sanchez F; Diaz-Rubio E
    BMC Cancer; 2012 Jun; 12():260. PubMed ID: 22712570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers.
    Gulati S; Martinez P; Joshi T; Birkbak NJ; Santos CR; Rowan AJ; Pickering L; Gore M; Larkin J; Szallasi Z; Bates PA; Swanton C; Gerlinger M
    Eur Urol; 2014 Nov; 66(5):936-48. PubMed ID: 25047176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a 55-gene classifier as a prognostic biomarker for adjuvant chemotherapy in stage III colon cancer patients.
    Oki E; Shinto E; Shimokawa M; Yamaguchi S; Ishiguro M; Hasegawa S; Takii Y; Ishida H; Kusumoto T; Morita M; Tomita N; Shiozawa M; Tanaka M; Ozawa H; Hashiguchi Y; Ohnuma S; Tada S; Matsushima T; Hase K
    BMC Cancer; 2021 Dec; 21(1):1332. PubMed ID: 34906120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic and predictive value of an autophagy-related signature for early relapse in stages I-III colon cancer.
    Mo S; Dai W; Xiang W; Li Y; Feng Y; Zhang L; Li Q; Cai G
    Carcinogenesis; 2019 Jul; 40(7):861-870. PubMed ID: 30933267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma.
    Qu L; Wang ZL; Chen Q; Li YM; He HW; Hsieh JJ; Xue S; Wu ZJ; Liu B; Tang H; Xu XF; Xu F; Wang J; Bao Y; Wang AB; Wang D; Yi XM; Zhou ZK; Shi CJ; Zhong K; Sheng ZC; Zhou YL; Jiang J; Chu XY; He J; Ge JP; Zhang ZY; Zhou WQ; Chen C; Yang JH; Sun YH; Wang LH
    Eur Urol; 2018 Dec; 74(6):756-763. PubMed ID: 30143382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of
    Ma WR; Xu P; Liu ZJ; Zhou J; Gu LK; Zhang J; Deng DJ
    World J Gastroenterol; 2020 Jan; 26(2):184-198. PubMed ID: 31988584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Translating tumor biology into personalized treatment planning: analytical performance characteristics of the Oncotype DX Colon Cancer Assay.
    Clark-Langone KM; Sangli C; Krishnakumar J; Watson D
    BMC Cancer; 2010 Dec; 10():691. PubMed ID: 21176237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.
    Seiler R; Ashab HAD; Erho N; van Rhijn BWG; Winters B; Douglas J; Van Kessel KE; Fransen van de Putte EE; Sommerlad M; Wang NQ; Choeurng V; Gibb EA; Palmer-Aronsten B; Lam LL; Buerki C; Davicioni E; Sjödahl G; Kardos J; Hoadley KA; Lerner SP; McConkey DJ; Choi W; Kim WY; Kiss B; Thalmann GN; Todenhöfer T; Crabb SJ; North S; Zwarthoff EC; Boormans JL; Wright J; Dall'Era M; van der Heijden MS; Black PC
    Eur Urol; 2017 Oct; 72(4):544-554. PubMed ID: 28390739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and validation of a seven-gene prognostic marker in colon cancer based on single-cell transcriptome analysis.
    Zhou Y; Guo Y; Wang Y
    IET Syst Biol; 2022 Apr; 16(2):72-83. PubMed ID: 35352485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular subtypes of pancreatic cancer based on miRNA expression profiles have independent prognostic value.
    Namkung J; Kwon W; Choi Y; Yi SG; Han S; Kang MJ; Kim SW; Park T; Jang JY
    J Gastroenterol Hepatol; 2016 Jun; 31(6):1160-7. PubMed ID: 26644397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study.
    Dienstmann R; Mason MJ; Sinicrope FA; Phipps AI; Tejpar S; Nesbakken A; Danielsen SA; Sveen A; Buchanan DD; Clendenning M; Rosty C; Bot B; Alberts SR; Milburn Jessup J; Lothe RA; Delorenzi M; Newcomb PA; Sargent D; Guinney J
    Ann Oncol; 2017 May; 28(5):1023-1031. PubMed ID: 28453697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SOX9 expression predicts relapse of stage II colon cancer patients.
    Marcker Espersen ML; Linnemann D; Christensen IJ; Alamili M; Troelsen JT; Høgdall E
    Hum Pathol; 2016 Jun; 52():38-46. PubMed ID: 26980019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcriptome profiling reveals an integrated mRNA-lncRNA signature with predictive value of early relapse in colon cancer.
    Dai W; Feng Y; Mo S; Xiang W; Li Q; Wang R; Xu Y; Cai G
    Carcinogenesis; 2018 Oct; 39(10):1235-1244. PubMed ID: 29982331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of an Immune Signature Predicting Prognosis Risk and Lymphocyte Infiltration in Colon Cancer.
    Li X; Wen D; Li X; Yao C; Chong W; Chen H
    Front Immunol; 2020; 11():1678. PubMed ID: 33013820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 101.